< Back to previous page
Researcher
Georg Halder
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Georg Halder (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Growth Control and Cancer Research (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - Laboratory of Growth Control and Cancer Research (VIB-KU Leuven) (Division)
Member
From1 Jan 2017 → Today - Halder Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Human Genetics (Department)
Member
From1 May 2012 → 31 Dec 2016
Projects
1 - 10 of 39
- Hippo Signaling in Lipid Metabolism: A Drosophila Approach to unravel Obesity ComplexitiesFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Action of Hippo pathway inhibitors on liver cancer in miceFrom6 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Action of Hippo pathway inhibitors on liver cancer in miceFrom5 Dec 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Action of Hippo pathway inhibitors on liver cancer in miceFrom1 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Hippo signaling pathway in liver cancer or liver regenerationFrom4 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding a novel tissue surveillance mechanism that suppresses liver cancerFrom11 May 2022 → TodayFunding: FWO fellowships
- Understanding the role of the Hippo pathway in chronic liver disease and liver cancerFrom15 Mar 2022 → 30 Aug 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the Role of Endothelial-epithelial Mechanical Interactions in Shaping Mini-organsFrom27 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding the anti-cancer effects of new YAP/TAZ inhibitors to treat malignant mesotheliomaFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Suppressing the evolution of liver cancer into highly aggressive formsFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
Publications
1 - 10 of 57
- The Cell Competition Theory of Cancer(2024)
Authors: Ana Algueró Nadal, Georg Halder
- Cell competition induced by relative differences in levels of Yap/Taz causes lethal autophagy in liver cancer.(2024)
Authors: Soheil Soheily, Georg Halder
- Single-cell spatial multi-omics and deep learning dissect enhancer-driven gene regulatory networks in liver zonation(2024)
Authors: Valerie Christiaens, Jonas Demeulemeester, David Mauduit, Georg Halder, Stein Aerts
- A novel irreversible TEAD inhibitor, SWTX-143, blocks Hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models.(2023)
Authors: Hanne Hillen, Weronika Kowalczyk, Patrick Chaltin, Georg Halder
Pages: OF1 - OF11 - Shared enhancer gene regulatory networks between wound and oncogenic programs(2023)
Authors: Seppe De Winter, Georg Halder, Stein Aerts
- SW-682: A novel TEAD inhibitor for the treatment of cancers bearing mutations in the Hippo signaling pathway(2023)
Authors: Georg Halder
- In vivo effects of novel YAP/TAZ-TEAD inhibitors(2023)
Authors: Hanne Hillen, Georg Halder
- Reverse engineering cellular identity at single-cell resolution(2023)
Authors: Carmen Bravo González-Blas, Stein Aerts, Georg Halder
- Hippo signaling instructs ectopic but not normal organ growth(2022)
Authors: Weronika Kowalczyk, Hanne Hillen, Jun Xie, Soheil Soheily, Ivan Moya, Stein Aerts, Georg Halder
Pages: 744 - + - Novel antagonists of TEAD palmitoylation inhibit the growth of Hippo-altered cancers in preclinical models(2022)
Authors: Georg Halder
Patents
1 - 2 of 2